Items Tagged ‘B-raf mutations’

June 6, 2017

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer


Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer patients have a B-raf mutation that can be specifically targeted by existing cancer drugs. The […]

View full entry

Tags: B-raf mutations, mekinist, News, papillary thyroid cancer, precision medicine, tafinlar, targeted therapy, Thyroid Cancer